Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cyclophosphamide + Fludarabine
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 18 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Fludarabine Fludara FAMP|Fludarabine phosphate Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06096038 Phase Ib/II iC9.CAR-CSPG4 T cells Cyclophosphamide + Fludarabine Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Recruiting USA 0
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT03938987 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) Recruiting CAN 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT06237881 Phase Ib/II Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT05681780 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC Recruiting USA 0
NCT06205290 Phase III Idelalisib + Rituximab Lisocabtagene maraleucel Cyclophosphamide + Fludarabine Bendamustine + Rituximab A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies Withdrawn USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT 2
NCT03139370 Phase I Cyclophosphamide + Fludarabine KITE-718 Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers Terminated USA 0
NCT06305299 Phase I Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells Not yet recruiting USA 0
NCT05418088 Phase I Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Recruiting USA 0
NCT06128044 Phase I CB-012 Cyclophosphamide + Fludarabine CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMpLify) Recruiting USA 0
NCT05972720 Phase II Cyclophosphamide + Fludarabine CRG-022 A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05114837 Phase Ib/II CAR19-tTreg Cyclophosphamide + Fludarabine Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL Not yet recruiting USA 0
NCT06241456 Phase I Cetuximab + FT825 Bendamustine + Cisplatin + Docetaxel FT825 Cyclophosphamide + Fludarabine FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors Recruiting USA 0
NCT06399393 Phase III Cyclophosphamide + Fludarabine Idecabtagene Vicleucel + Lenalidomide A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT06415487 Phase I Cyclophosphamide + Fludarabine ACE2016 + Pembrolizumab ACE2016 ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Not yet recruiting 0
NCT03721068 Phase I iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma Recruiting USA 0
NCT03907852 Phase Ib/II Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA | CAN 0
NCT03624036 Phase Ib/II Cyclophosphamide + Fludarabine axicabtagene ciloleucel Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) Terminated USA | ITA 0
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT00881920 Phase I CAR.k.28 cells Cyclophosphamide + Fludarabine Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) Recruiting USA 0
NCT05694364 Phase I PRGN-3007 Cyclophosphamide Cyclophosphamide + Fludarabine Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Recruiting USA 0
NCT05703854 Phase Ib/II CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma Recruiting USA 0
NCT05347485 Phase II Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma Completed USA 0
NCT00167180 Phase II Cyclophosphamide + Fludarabine Post Transplant Donor Lymphocyte Infusion Terminated USA 0
NCT05672459 Phase Ib/II IVS-3001 Cyclophosphamide + Fludarabine A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors Recruiting USA 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03089203 Phase I CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine CART-PSMA-TGFbetaRDN Cells for Castrate-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Active, not recruiting CAN 0
NCT05949125 Phase I Cyclophosphamide + Fludarabine AVC-201 Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 Recruiting NLD | DEU 0
NCT04678336 Phase I CART123 cells Cyclophosphamide + Fludarabine CD123 Redirected T Cells for AML in Pediatric Subjects Active, not recruiting USA 0
NCT04088890 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed USA 0
NCT04892277 Phase I Bendamustine IC19/1563 Cyclophosphamide + Fludarabine CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Recruiting USA 0
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT05310591 Phase Ib/II Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) Recruiting FRA 0
NCT04323657 Phase Ib/II Cyclophosphamide + Fludarabine TC-110 T-cells TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Completed USA 0
NCT06119685 Phase Ib/II IDP-023 Cyclophosphamide + Fludarabine Daratumumab + IDP-023 Aldesleukin + IDP-023 IDP-023 + Rituximab IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Recruiting USA 0
NCT05883449 Phase II AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) Recruiting USA 0
NCT03971799 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD33 CART cells Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT05678205 Phase Ib/II AB-201 Cyclophosphamide + Fludarabine A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors Not yet recruiting USA 1
NCT05633615 Phase II Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05371093 Phase III axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) Recruiting USA | ITA | GBR | FRA | ESP | DEU 1
NCT04074746 Phase I Cyclophosphamide + Fludarabine AFM13 Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Active, not recruiting USA 0
NCT04314843 Phase Ib/II axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) Terminated USA 0
NCT04310592 Phase I Cyclophosphamide + Fludarabine CYNK-001 Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) Recruiting USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT06236139 Phase Ib/II Cyclophosphamide + Fludarabine Anti-STEAP1 CAR-T cells + Enzalutamide Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Not yet recruiting USA 0
NCT04245839 Phase II Lisocabtagene maraleucel Cyclophosphamide + Fludarabine A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 2
NCT05495464 Phase I Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma Recruiting USA 0
NCT06094842 Phase I L1CAM-specific CAR+EGFRt+ T cells Bendamustine Cyclophosphamide + Fludarabine Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Not yet recruiting USA 0
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Recruiting USA 0
NCT05218408 Phase Ib/II Cyclophosphamide + Fludarabine CYNK-001 CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) Withdrawn 0
NCT04608487 Phase I Cyclophosphamide + Fludarabine axicabtagene ciloleucel Axi-cel in CNS Lymphoma Active, not recruiting USA 0
NCT05451849 Phase Ib/II Cyclophosphamide + Fludarabine TC-510 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA 0
NCT02153580 Phase I Etoposide Cyclophosphamide + Fludarabine Bendamustine Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Active, not recruiting USA 0
NCT00003553 Phase II Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer Completed USA 0
NCT04099797 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) Recruiting USA 0
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Active, not recruiting USA | NLD 0
NCT06285422 Phase I Cyclophosphamide + Fludarabine SC262 Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Recruiting USA 0
NCT04526509 Phase I Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors Terminated USA | NLD | DEU | CAN | AUS 1
NCT03016377 Phase Ib/II Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL Recruiting USA 0
NCT04848064 Phase I Cyclophosphamide + Fludarabine Mogamulizumab Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Recruiting USA 0
NCT05748197 Phase I Cyclophosphamide + Fludarabine ADCLEC.syn1 A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia Recruiting USA 0
NCT04088864 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Active, not recruiting USA 0
NCT05989828 Phase I Cyclophosphamide + Fludarabine Autologous anti-HLA-A2/NY-ESO-1 TCR T cells A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer Not yet recruiting USA 0
NCT05707273 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission Recruiting USA 0
NCT06043713 Phase I Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations Recruiting USA 0
NCT03233854 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells NKTR-255 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT06153251 Phase I BMS-986453 Cyclophosphamide + Fludarabine A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Recruiting USA | FRA | ESP | DEU 0
NCT05963217 Phase I Cyclophosphamide + Fludarabine TBI-2001 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL Recruiting CAN 0
NCT06253520 Phase I Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Recruiting USA 0
NCT05625594 Phase I Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells Cyclophosphamide + Fludarabine Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma Recruiting USA 0
NCT06079164 Phase I KITE-197 Cyclophosphamide + Fludarabine Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma Recruiting USA | CAN | AUS 0
NCT04551885 Phase I Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05400109 Phase I Cyclophosphamide + Fludarabine UF-KURE19 Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas Active, not recruiting USA 0
NCT02995330 Phase I Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer Terminated USA 0
NCT04809766 Phase I Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT05618925 Phase I Cyclophosphamide + Fludarabine CD19 t-haNK cells + Rituximab CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma Not yet recruiting USA 0
NCT02869217 Phase I Cyclophosphamide + Fludarabine TBI-1301 Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Active, not recruiting CAN 0
NCT03873805 Phase I Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR T-cells PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT05442515 Phase Ib/II CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT02932956 Phase I Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) Active, not recruiting USA 0
NCT05588440 Phase Ib/II Cyclophosphamide + Fludarabine ONCT-808 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT03241940 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Recruiting USA 0
NCT02774291 Phase I Aldesleukin Cyclophosphamide + Fludarabine Filgrastim Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 Terminated USA 0
NCT05628883 Phase I Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Recruiting USA 0
NCT05922930 Phase Ib/II TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer Recruiting USA 0
NCT04614636 Phase I Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 FT538 in Subjects With Advanced Hematologic Malignancies Terminated USA 0
NCT05878184 Phase I Cyclophosphamide + Fludarabine SC291 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Recruiting USA | AUS 0
NCT05077527 Phase I axicabtagene ciloleucel Cyclophosphamide + Fludarabine Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Not yet recruiting 0
NCT04714372 Phase I Cyclophosphamide + Fludarabine Daratumumab and hyaluronidase-fihj + FT538 FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Active, not recruiting USA 0
NCT05110742 Phase Ib/II CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances Recruiting USA 0
NCT06191887 Phase I Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Recruiting USA 0
NCT04377932 Phase I Cyclophosphamide + Fludarabine AGAR T cells Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Recruiting USA 0
NCT06341647 Phase I Cyclophosphamide + Fludarabine AB-201 Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 Not yet recruiting AUS 0
NCT02905188 Phase I GLYCAR T cells Cyclophosphamide + Fludarabine Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) Completed USA 0
NCT05797233 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Recruiting USA 0
NCT04196413 Phase I Cyclophosphamide + Fludarabine GD2 CAR T cells GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) Recruiting USA 0
NCT06347068 Phase I iC9-CAR.B7-H3 T-cells Cyclophosphamide + Fludarabine Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells Not yet recruiting USA 0
NCT03338972 Phase I Cyclophosphamide + Fludarabine Anti-BCMA CAR T Cells Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma Completed USA 0
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Active, not recruiting USA 0
NCT03912831 Phase I Cyclophosphamide + Fludarabine KITE-439 Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers Terminated USA 0
NCT06326463 Phase I CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Not yet recruiting USA 0
NCT06343376 Phase I EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Recruiting USA 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT06066424 Phase I Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Recruiting USA 0
NCT05886491 Phase Ib/II Cyclophosphamide + Fludarabine GDX012 A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT01853631 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) Recruiting USA 0
NCT05478837 Phase I Cyclophosphamide + Fludarabine KIND T cells Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018) Recruiting USA 0
NCT05665062 Phase I Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Recruiting USA 0
NCT05182073 Phase I Cyclophosphamide + Fludarabine FT576 Daratumumab + FT576 FT576 in Subjects With Multiple Myeloma Recruiting USA 0
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting USA 0
NCT05334329 Phase I Cyclophosphamide + Fludarabine Atezolizumab TRACK-NK cells Genetically Engineered Cells (COH06) With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Recruiting USA 0
NCT06026319 Phase I CD79b-19 CAR T cells Cyclophosphamide + Fludarabine CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Recruiting USA 0
NCT06043323 Phase II axicabtagene ciloleucel Cyclophosphamide + Fludarabine A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma Recruiting USA 0
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Completed USA | DEU 0
NCT05639972 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin + E7 TCR T-cells E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers Not yet recruiting USA 0
NCT06358430 Phase I Cyclophosphamide + Fludarabine Cetuximab + TROP2-CAR/IL15-transduced CBNK cells Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) Not yet recruiting USA 0
NCT06190249 Phase I Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma Not yet recruiting USA 0
NCT00338377 Phase II Cyclophosphamide + Fludarabine Aldesleukin Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma Active, not recruiting USA 0
NCT06364423 Phase Ib/II Hu19-CD828Z T cells + Rituximab Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Not yet recruiting USA 0
NCT04639245 Phase Ib/II MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer Terminated USA 0
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Completed USA | DEU 0
NCT03019666 Phase I Allogeneic NAM NK cells Cyclophosphamide + Fludarabine Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Completed USA 0
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed USA 0
NCT05020015 Phase II iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Active, not recruiting USA 0
NCT04167696 Phase I CYAD-02 Cyclophosphamide + Fludarabine Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) Recruiting USA | BEL 0
NCT03448393 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT03704298 Phase Ib/II axicabtagene ciloleucel + Utomilumab Cyclophosphamide + Fludarabine Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) Terminated USA 0
NCT05032820 Phase II Cyclophosphamide + Fludarabine Idecabtagene Vicleucel + Lenalidomide MM CAR-T to Upgrade Response Active, not recruiting USA 0
NCT03287817 Phase Ib/II Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) Completed USA | GBR 0
NCT06236425 Phase I Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC Recruiting USA 0
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting USA 0
NCT06151847 Phase II Cyclophosphamide + Fludarabine Lifileucel Aldesleukin Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Recruiting USA 0
NCT05092451 Phase Ib/II CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Recruiting USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT05714345 Phase II Cyclophosphamide + Fludarabine ALLO-647 + Cyclophosphamide + Fludarabine ALLO-501A Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND) Recruiting USA | BEL | AUT 0
NCT04394650 Phase I Cyclophosphamide + Fludarabine CC-98633 A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma Active, not recruiting USA 0
NCT02830724 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR T cells Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Recruiting USA 0


Additional content available in CKB BOOST